Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company" or "Group")

Allergy Therapeutics announces the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director

-     Newly created Chief Strategy Officer role will drive long-term international growth strategy as Group advances next-generation pipeline and explores opportunities to deliver on global ambitions

-     Appointments strengthen Board, each bringing decades of expertise in their respective fields to support Company's ambition to become a global leader in allergy treatments

30 January 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the appointment of Helge Weiner-Trapness as Chief Strategy Officer. He also joins the Group's Board as an Executive Director.

Helge has more than 30 years of experience across leading global investment banks in the US and Asia. He most recently served as Vice Chairman, Global Banking at HSBC Holdings plc (LSE: HSBA; HKG: 0005), one of the world's largest financial organisations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. He was a Founding Partner of Hong Kong-based Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. Earlier, he held senior roles at Barclays Bank, Asia Pacific Land, J.P. Morgan Securities and Goldman Sachs.

In his newly created role as Chief Strategy Officer, Helge will drive Allergy Therapeutics' long-term growth strategy, including corporate development, partnership strategy and portfolio prioritisation as Allergy Therapeutics advances its next-generation pipeline and explores opportunities to deliver on its global ambitions.

Helge Weiner-Trapness, Chief Strategy Officer and Executive Director, said: "Allergy Therapeutics has established a leading position in its core markets, with a significant portfolio and an innovative pipeline that present a strong platform for future growth. I am looking forward to working with the Board and management team to drive the Company's long-term strategy and international development, prioritising opportunities and executing a global strategy in a disciplined and sustainable way."

Allergy Therapeutics also announces that Lawrence Allen Wang will join the Company's Board as an independent Non-Executive Director. Lawrence has more than 20 years' experience across healthcare and investment roles. He currently serves as Chief Financial Officer of Adicon Clinical Laboratories, Inc. (HKG: 9860), one of China's leading independent clinical laboratory service providers, where he played a key role in the company's financing and its listing on the Hong Kong Stock Exchange. Prior to Adicon, Lawrence held roles in private equity, asset management and investment banking groups, including positions at Vivo Capital, Primavera Capital, Macquarie Group and Goldman Sachs (Asia).

Lawrence Allen Wang, Independent Non-Executive Director, said: ""Allergy Therapeutics has built a strong clinical and commercial platform, and I look forward to supporting the Board as the Company continues to develop its international strategy to become a global leader in allergy treatments."

Peter Jensen, Chairman of Allergy Therapeutics, said: "On behalf of the Board, I am pleased to welcome Helge and Larry to Allergy Therapeutics. Both bring deep investment and healthcare expertise that will be instrumental as the Company pursues its long-term growth ambitions, including evaluating a potential dual listing on the Hong Kong Stock Exchange. These appointments reflect our continued focus on building a Board with the experience and perspective required to support the Company's next phase of international development."

Additional information in respect of the AIM Rules:

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES ("AIM RULES")

There is no further information to be disclosed in relation to the appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

[email protected] 

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries and branches in nine major European countries and via distribution agreements in an additional four countries. For more information, please see www.allergytherapeutics.com.